|
|
|||||||
Acute Myeloid Leukemia |
1 Department of Internal Medicine, Medical School of Ribeirao Preto, Brazil;
2 Molecular Biology Laboratory, HEMOPE, Brazil;
3 Bone Marrow Transplantation Unit, Hospital Amaral Carvalho, Brazil
4 Hematology Service, University of Minas Gerais, Brazil;
5 Hematology and Bone Marrow Transplantation Unit, HCPA, Brazil;
6 Hematology Service, Santa Casa de São Paulo, Brazil;
7 Fundação Pio XII de Barretos, Brazil;
8 Hematology Service; HCPR, Brazil;
9 Clínica de Hematologia de Ribeirão Preto, Brazil;
10 Department of Hematology and Hemotherapy, UNIFESP, Brazil;
11 Oncominas, Brazil;
12 Hemocentro, State University of Campinas, Brazil;
13 International Outreach Program, St. Jude Childrens Research Hospital, Memphis, TN, USA
Correspondence: Eduardo Magalhães Rego, Laboratório de Hematologia, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, São Paulo, 14048900, Brazil. Phone: international +55.16.36022888. Fax: international +55.16.36336695. E-mail: emrego{at}hcrp.fmrp.usp.br
We report an increased incidence of high relapse risk features in 157 APL Brazilian patients. Out of 134 patients treated with ATRA and anthracyclines, only 91 (67.9%) achieved remission because 43 (32%) died during induction. The death rate during consolidation was 10.5%. Bleeding complications were the most frequent cause of failure (21.6%).
Key words: acute promyelocytic leukemia, ATRA, developing countries, Brazil.
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |